Loading…
Loading…
Healthcare and biotech led last week's winners, with EPHE, BBC, HELX, XHS and SURI topping ETF gains as markets slid on AI worries and Fed uncertainty.
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma associated with mental health are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.
Blame inflation and rising interest rates, among other factors, but biotechnology mergers and acquisitions activity remains lethargic. That's despite a slump in biotech stocks dating back to early 2021 that is depressing share prices of potential targets.
Scientists have completed mapping the human genome. New research from the Telomere-to-Telomere (T2T) Consortium, a loose collaborative of about 100 scientists, shows that the team has completed a challenging 8% of the human genome left unresolved by the initial Human Genome Project.
Twenty-six exchange-traded products were added to the list, and 40 funds were removed, making August a busier month in terms of removals.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for HELX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.